Key Insights

Highlights

Success Rate

74% trial completion

Published Results

41 trials with published results (19%)

Research Maturity

79 completed trials (37% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

13.1%

28 terminated out of 214 trials

Success Rate

73.8%

-12.7% vs benchmark

Late-Stage Pipeline

14%

30 trials in Phase 3/4

Results Transparency

52%

41 of 79 completed with results

Key Signals

41 with results74% success28 terminated

Data Visualizations

Phase Distribution

171Total

Not Applicable (24)

Early P 1 (2)

P 1 (63)

P 2 (52)

P 3 (29)

P 4 (1)

Trial Status

Completed79

Unknown39

Recruiting37

Terminated28

Active Not Recruiting17

Not Yet Recruiting10

Trial Success Rate

73.8%

Benchmark: 86.5%

Based on 79 completed trials

Clinical Trials (214)

Showing 20 of 20 trials

NCT06386887Not ApplicableRecruitingPrimary

Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer

NCT00086567Completed

Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers

NCT03393884Phase 1Active Not RecruitingPrimary

Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2)

NCT06915025Phase 3RecruitingPrimary

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

NCT07545460Phase 3Not Yet RecruitingPrimary

A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer

NCT06994195Phase 3RecruitingPrimary

A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01)

NCT07303894Phase 2Recruiting

A Study of Isoquercetin in People With Ovarian Cancer

NCT05397093Phase 1TerminatedPrimary

ITIL-306 in Advanced Solid Tumors

NCT06890338Phase 2RecruitingPrimary

A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

NCT06305299Phase 1Recruiting

Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

NCT06395519Phase 1Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

NCT07432633Phase 1Recruiting

[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

NCT07495397Not ApplicableRecruitingPrimary

Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO/R1)

NCT04539327CompletedPrimary

Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study

NCT07480954Phase 1RecruitingPrimary

Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)

NCT06412510Phase 1Recruiting

Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT

NCT04027868CompletedPrimary

Genomic BRCA and Extensive ovArian Cancer Testing

NCT03862677RecruitingPrimary

Determining Prognostic Immune Markers in Patients With Ovarian Cancer

NCT05316181Phase 3Active Not RecruitingPrimary

CRS & HIPEC for Platinum-Resistant Recurrent Ovarian Cancer (KOV-02R, RECOVER)